Wells Pharmacy Network, LLC, Ocala, FL
Is Wells Pharmacy Network, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Wells Pharmacy Network, LLC hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH26249 for WELLS PHARMACY NETWORK, LLC, OCALA, status Clear and PH27462 for WELLS PHARMACY NETWORK, LLC, OCALA, status Clear. The California State Board of Pharmacy also lists nonresident license NRP 1333 for Wells Pharmacy Network Llc, Ocala, FL, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6079 for Wells Pharmacy Network, LLC, Ocala, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018020 for WELLS PHARMACY NETWORK LLC, OCALA, FL, status INOPERATIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002385 for WELLS PHARMACY NETWORK LLC, OCALA, FL, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001159 for Wells Pharmacy Network, LLC, OCALA, FL, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009886 for Wells Pharmacy Network LLC, Ocala, FL, status Active, as of Nov 10, 2026.
Has Wells Pharmacy Network, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jun 8, 2020) for Wells Pharmacy Network, LLC. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 3 actions: “Administrative Complaint Filed” dated May 12, 2025, case 202449572 on license PH27462, “Obligation(s) Satisfied” dated Jul 9, 2020, case 201940934 on license PH26249 and “Administrative Complaint Filed” dated Dec 16, 2019, case 201940934 on license PH26249. The Colorado State Board of Pharmacy’s license dataset also lists 4 actions: “CLS Letter of Admonition” dated Apr 8, 2025, case 2024-9567 on nonresident license OSP 6079, “CLS Letter of Admonition” dated Jun 13, 2023, case 2023-1278 on nonresident license OSP 6079 and “CLS Letter of Admonition” dated Oct 31, 2018, case 2018-4901 on nonresident license OSP 6079, and more listed below.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Wells Pharmacy Network, LLC
- Location
- Ocala, FL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 8, 2020
- FDA Data Dashboard inspections
- 10 inspections: 8 OAI, 2 VAI; 5 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 24 observations
- State board records
- License found: PH26249, Clear; PH27462, Clear
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Wells Pharmacy Network, LLC, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Jun 8, 2020 | FMD-145 letter | FMD-145 Letter Issued 06/8/2020 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Wells Pharmacy Network LLC, Ocala, FL (FEI number 3006228598), matched to this page by exact name, city and state. It lists 10 inspections: 8 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 22, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006228598 | 1056599 |
| Sep 13, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3006228598 | 983673 |
| Jun 19, 2014 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006228598 | 884768 |
| Mar 7, 2014 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006228598 | 869135 |
| Jul 26, 2013 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3006228598 | 843527 |
| May 11, 2012 | Official Action Indicated (OAI) | Food Composition, Standards, Labeling and Econ (Food/Cosmetics): No Action Indicated (NAI); Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3006228598 | 779546 |
| Dec 4, 2009 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3006228598 | 633184 |
| Jun 23, 2009 | Official Action Indicated (OAI) | Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary) | 3006228598 | 592708 |
| May 20, 2009 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3006228598 | 583347 |
| Feb 3, 2009 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006228598 | 559420 |
Form 483s FDA has published for this site
- Jul 26, 2018: Form 483 to Wells Pharmacy Network LLC, published Jan 17, 2024. fda.gov
- Oct 4, 2016: Form 483 to Wells Pharmacy Network LLC, published Jan 17, 2024. fda.gov
- Jul 17, 2015: Form 483 to Wells Pharmacy Network LLC, published Jan 17, 2024. fda.gov
- Jul 10, 2015: Form 483 to Wells Pharmacy Network LLC, published Jan 17, 2024. fda.gov
- Jul 10, 2015: Form 483 to Wells Pharmacy Network LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 24 numbered observations in all, across 2 inspections ending Mar 7, 2014 to Jun 19, 2014. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 30, 2014 to Jun 19, 2014: 13 observations
- Firm on the cover
- Wells Pharmacy Network LLC, 1210 sw 33rd Ave Type Establis hment Inspected Producer of Sterile Drugs, Ocala, FL 34474-2853
- FDA district office on the cover
- Not read
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established, written, and followed.
Specifically, the media fills used to qualify operators to perfonn sterile production do not include: A. Growth promotion tests on the media used in media fills. B. Environmental monitoring during fingertip sampling and media fills.
- This is a repeat observation and was listed as observation 1 on the fda 483 dated 03/07/2014 and observation 2 on the FDA 483 dated 7/26/13
Observation 2
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically, the most recent qualification ofthe ISO 7 cleanroom and the ISO 5 laminar air flow hoods completed on 12/13/ 13 by a contractor does not include: A. Performance under dynamic conditions. B. Documentation of air flow studies (smoke studies) under the Laminar Air Flow Workstation where sterile products are processed. C. Documentation to show that quality reviewed the qualificat ion.
This is a repeat observation and was listed as Observation 2 on the FDA 483 dated 03/07/2014 and Observation 7 on the FDA 483 dated 07/2612013.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. Surface and air monitoring of the ISO 5 Laminar Air flow workstation used in the production of sterile ddrugs is on ly conducted on a redacted b4 basis and sterile drug products are prepared in tehse hoods redacted b4. B. Personnel monitoring, including fingertip sampling, of operatoers involved in daily sterile operations of processing sterile drug products in the ISO 5 LAFW is only conducted on a redacted b5 basis. Personnel monitoring, including fingertip sampling, of operatoers involved in daily sterile operations of processing sterile drug products in the ISO 5 LAFW is only conducted on a redacted b5 basis.Personnel monitoring, including fingertip sampling, of operatoers involved in daily sterile operations of processing sterile drug products in the ISO 5 LAFW is only conducted on a redacted b5 basis. C. Growth promotion testing is not performed for the redacted b4 media used for your firm's enviornmenta l monitoring program to ensure that is promotes growth og gram postive and gram negative bacteria, yeast and molds. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, the suitability, efficacy, and limitations of disinfecting agents have not been assessed to ensure contaminants are adequately removed from surfaces in the ISO classified areas.
This is a repeat observation and was listed as Observation 4 on the FDA 483 dated 03 /07/2014 and Observation 6 on the FDA 483 dated 07/26/2013.
Observation 5
Each batch ofdrug product required to be free ofobjectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, the documentation you provided does not establish that a method validation was performed for the redacted b4 instrument, redacted b4 that you use for sterlily testing for all of your sterile products produced at your firm, including but not limited to, Sermorelin Accetate products. Additionally, you have no documentation defining the results revents vs microbe the prodess forevluating events, or documentation showing the evaluation of events when they do occcur. • Specifically , the documentation you provided does not establish that a method validation was pe rformed for the redacted b4 instrument, redacted b4 that you use for sterlily testing for all of your sterile products produced at your firm, including but not limited to, Sermorelin Accetate products. Additionally, you have no documentation defining the results revents vs microbe the prodess forevluating events, or documentation showing the evaluation of events when they do occcur. ...
Observation 6
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, you have no written procedures or scientific data to ensure that the lyophilization cycle is appropriate for the Sennorelin Acetate finished products youc finn produces.
A. Firm personnel explained the production process for semorelin acccetate/ghrp 2 lyophilized 9mg/3mg and stated that the lot is placed in the lyophilizer for redacted b4d and after a visual inspection, if the power does not appear to be dry, the lot remain in the lyophilizer longer. Firm personnel explained the production proces s fo r semorelin acccetate/ghrp 2 lyophilized 9mg/3mg and stated that t he lot is placed in the lyophilizer for redacted b4d and after a visual inspection, if the power does not appear to be dry, the lot remain in the lyophilizer longer. B. The Director ofQuality Assurance stated that the lyophilizer is programmed to reach the desired temperature and pressure and that no validation has been conducted regarding the process for the Sennorelin Acetate finished products.
Observation 7
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm lacks written procedures for a stability program and realible scientific data to support the 1 80 dauy beyond use data assigned to the semorelin acccetate finished products. The only data provi de d was a redact ed b4 study for one semorelin acetate products, although you produce numberous different formulas. Firm personnel s tated that you rely on scientific literature to establish beyond the use dates without actually conducting any studies.
Furthermore, 14 ofthe 17 Logged Fonnula Worksheets for Sermorelin Acetate reviewed contained two beyond-use dates which were conflicting. For example: 07/31/2014 and 07/28!20 14 were both listed as the beyond-use date on your Logged Formula Worksheet for Sermorelin Acetate!GHRP (2) Lyophilzed 9mg/3mg Vial, Lot #0 1282014@48. Additionally, the label for the bottle ofSemorelin Acetate 9mg, Lot #01282014-48 was assigned a Use By date of07/2014. ...
Observation 8
The written stability program does not include testing of drug products for reconstitution after they are reconstituted.
Specifically, your fll11llacks written procedures for a stability program and reliable scientific data to support the 180 day beyond-use date assigned to the Sermorelin Ace~e finished products, once the product is reconstituted. Firm personnel
stated that you rely on scientific literature to establish beyond-use dates without actually conducting any studies.
Additionally, your finn does not assign a separate beyond-use date for the Sennorelin Acetate finished products that are to be
reconstituted after they are dispensed.
Observation 9
Clothing of personnel engaged in the processing ofdrug products is not appropriate for the duties they perform.
Specifically, the gowns worn by operators engaged in processing ofsterile drug products in the ISO 5 Laminar Air Flow Workstations are not purchased sterile and are not sterilized by the finn. Finn personnel confirmed that they do not purchase sterile gowns or sterilize the gowns worn, and that gowns are reused in aseptic processing. Your production employees wear these non-sterile gowns while conducting operations using the ISO 5 Laminar Air Flow Workstation (LAFW), which includes placing their gowned arms inside the working area ofLAFW.
This is a repeat observation and was listed as Observation 7 on the FDA 483 dated 03 /07/2014 and Observation 3 on the FDA 483 dated 07/26120 13.
Observation 10
The quality control unit lacks the responsibility and authority to approve and reject all drug products.
Specifically,
A. The Director of Quality Assurance stated that the release of finished drug product for shipment is conducted by the fmn's Pharmacists, who are not part ofthe Quality Assurance Unit The Quarantine Testing forms, covering 03/18-06112/2014 and the Inhouse Quarantine Testing forms, covering 03/11-06/12/ 14, which your fmn uses for fmished product release, are initialed by the pharmacists. ·
(b) (4) B.The q uality control unit has not reviewed any of the daily control records sheets, s ince the redacted b4 instrument redacted b4 was installed on 7/3/2013. These sheets document the system suitability checks for the firm's inhouse redaccted b5 scanner used for testing and release of sterile products, including but not limited to, the Semoreline acetate products. The quality control unit ha s not reviewed any of the daily control records sheets, since the redacted b4 instrument redacted b4 was installed on 7/3/2013. ...
Observation 11
Batch production and control records do not include complete information relating to the production and control ofeach
batch.
Specifically,
Your finn does not document all batch related activities on the Logged Formula Worksheets for each batch prepared.
A. The lyophilization process was not listed on 17 of the 17 Logged Fonnula Worksheets that were reviewed for the Lyophilzed Sennorelin A~etate produ~ts prepared by your finn. There were no other re~ords available documenting the lyophilization pro~ess for these bat~hes . B. Four ofthe 17 Logged Fonnula Worksheets reviewed for the Sennorelin A~tate produ~ts prepared by your firm contained a handwritten number indicating the actual number of vials prepared, which contradicted the typed number documented on the Worksheet. I was unable to determine the actual batch yield for these lots. Finn personnel stated that the typed number for batch yield is not always the amount prepared.
Observation 12
Establishment ofthe reliability ofthe component supplier's report of analyses is defi~ient in that the test results are not appropriately validated at appropriate intervals.
Specifically, for analytical test results, your ely on the cceritificate of analysis provided by your contact laboratory; however , you have not established the reliabbilty of analysses thourgh either third party testing, on site auidts , or any other means.
Observation 13
·
Procedures describing the handling ofwritten and oral complaints related to drug products are not written or followed.
Specifically, your firm is not following your proccedure, compliant heanding sop 5.0300, version 1, effective 10/01/2012 in that:
A. The complaint regarding Semorelin Acetate/GHRP 2 received on 5/16/2014, remains open and was not closed out in the r edacted b4 time frame required to section 9.5.2. of your SOP..The complaint regarding Semorelin Acetate/GHRP 2 received on 5/16/2014, remains open and was not closed out in the redacted b4 time frame required to section 9.5.2. of your SOP B. The full complaint investigation has not been documented regarding the Sermorelin Acetate/GHRP (2) complaint r~ived on 05/16/2014 . C. The Customer Complaint Record required by Section 9.4 ofyour SOP to document complaints is not used. D. Complaint numbers are not assigned as required by Section 9.3 ofyour SOP.
This is a repeat observation and was listed as Observation 9 on the FDA 483 dated 03/07/2014.
• DATES OF INSPECI'ION : OS/30/2014(Fri). 06/03/2014(Tue), 06/09/2014(Mon), 06/l0/2014(Tue), 06/l312014(Fri), 06/1912014(Thu)
01\TE ISSUED
Inspection Feb 21, 2014 to Mar 7, 2014: 11 observations
- Firm on the cover
- Wells Pharmacy Network LLC, 1210 SW 33rd Ave, Ocala, FL 34 47 4- 2853
- FEI number
- 3006228598
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established, written, and followed.
Specifically,
The media fills associated with operator qualification for steriJe product compounding personnel are inadequate. Some deficiencies include but are not limited to:
A. The media fills associated with initial operator qualification for sterile product compounding personnel do not incorporate worst case conditions such as longer process times, most complex process, extended exposure ofcomponents, interruptions/breaks, or other applicable routine situations that could potentially impact tbe sterility ofthe product.
B. Growth promotion tests are not conducted on the media used for media fills.
C. Environmental monitoring and fingertip sampling was not conducted during media fills.
This is a repeat observation and was listed as Observation 2 on the FDA 483 dated 07/26/t3.
Observation 2
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air ffiters under positive pressure.
SpecificaUy, the most recent qualification ofthe lSO 7 cleaoroom and the lSO 5 laminar air flow boods completed on 12/13/13 by a contractor was not perfonned under dynamic conditions. In addition, the smoke studies completed on 12/13/13 in the lSO 5 LAFW were reported as acceptable, but were not recorded to verify the adequacy of!be laminar air flow and did not document that they were conducted under dynamic conditions. Finn personnel confirmed that employees did not - participate during tbe perfonnance of the smoke studies.
This is a repeat observation and was listed as Observa__ti<;>p. 7 on the FDA 483 dated 07/26/13.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. No environmental monitoring was conducted between 7/27-09/15/13 and 12/18/13-02/04/2014. During this time period your firm producted redacted b(4) lots of Avasin finished product syringes that were distributed.
B. You are not conducting, at least on a daily basis, surface and air monitoring ifthe ISO 5 LAFW, despite production of sterile drug products.
C. You are not conducting, at least on a daily basis, personnel monitoring, including fingertip sampling, ofoperators involved in sterile operations ofsterile drug products in the IS0-5 LAFW.
D. Growth promotion testing is not performed for the TSA and SDA media nsed for your firm's environmental monitoring program to ensure that is promotes growth ofgram positive and gram negative bacteria, yeast and molds.
This is a repeat observation and was listed as Observation 5 on the FDA 483 dated 07/26/13.
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, the suitability, efficacy, and limitations ofdisinfecting agents have not been assessed to ensure potential
~ contaminants are adequately removed from surfaces in the ISO classified areas.
This is a repeat observation and was listed as Observation 6 on the FDA 483 dated 07/26/13.
Observation 5
Each batch ofdrug product required to be free ofobjectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, the Avastin finished product syringes produced by your fim1 have not undergone microbiological method suitability testing for finished product release testing. Additionally, your firm is not testing the Avastin finished product syringes for endotoxins.
Thls is a repeat observation and was listed as Observation 10 on the FDA 483 dated 07/26/13.
Observation 6
There is no written testing program designed to assess the stability characteristics ofdrug products.
Specifically, your firm lacks written procedures for a stability program and reliable analytical data to support the 90 day beyond-use date assigned to the Avastin finished product syringes that your firm repackages. You sQlely rely on scientific literature to establish beyond-use dates for Avastin and there is no assurance, with the lack ofscientific data, that your Avastin finished product syringes will remain sterile or maintain potency throughout the expiry period. The following is an example ofthe beyond-use dates assigned: Avastin, 310 0.05 ML Syringe, Lot #11012013@67 was assigned a 90 day beyond-use date ofJnnuary 30, 2014 Avastin, 310 0.05 ML Syringe, Lot #11222013@66 was assigned a 90 day beyond-use date ofFebruary 20,2014 ·
This is are eat observation and was listed as Observation 8 on the FDA 483 dated 07/26/13.
Observation 7
Clothing ofpersonnel engaged in the processing ofdrug products is not appropriate for the dutie.o; they perfom1.
Specifically, I observed the gowns wom by personnel engaged in the processing ofsterile drug products in the ISO 5 laminar flow hoods were not sterile. Additionally, I observed fum personnel hang their gowns on a hanger in the anteroom for reuse in the sterile compounding area. Firm personnel confirmed that they do not purchase sterile gowns and that they reuse gowns in the sterile compounding area.
This is are eat observation and was listed as Observation 3 on the FDA 483 dated 07!16/13.
Observation 8
Procedures describing the calibration ofinstruments, apparatus, gauges and recording devices are not written or followed.
(b) (4) Specifically, there is no written protocol or documentation to demonstrate the redacted (b) (4) has been initially qualified to demonstrate the instrument is maintaining required limits for accuracy and prec1s1on. This instrument was used for finished product release ofyour sterile compounded products and specifically, the following lots of Avastin produced during the time frame of09/11-12/30/13: 09112013@48, 09172013@72, 09242013@52, 09302013@83,
10012013@15, 10082013~5, 10172013~2,10242013~59, 10282013@93, 10312013~6. 11012013@67, 11042013 87, 11062013 6, and 12102013 118.
Observation 9
Procedures describing the handling of written and oral complaints related to drug products are not written or followed.
Specifically, you have not documented all ofthe complaints your finn has received regarding your preparation containing
A vastin. On 0212112014, firm personnel stated that approximately one week ago you were informed by a physician ofa patient with an eye infection possibly caused by your preparation containing Avastin, which your pharmacy personnel bad prepared and dispensed. As of02/27/2014, the complaint was not logged and your fLrm did not have documentation ofa complaint investigation.
Your firm had received two earlier complaints regarding your preparation containing Avastin. The complaint received 12/18/2013 reported the patient received a staph-like infection. The complaint received Ol/14/2014 reported a case of endophthalmitis in one patient.
Observation 10
Investigations of did not extend t.o other batches ofthe same drug product.
Specifically, your firm has not investigated and determined the root cause for the following three complaints related to your A vastin preparations:
A. On 12/18/2013, your firm received a complaint that a patient received a staph-like infection after an injection from Master Lot # 11222013@66
B. On 01/14/2014, your firm received a report ofa patient with a case ofendophthalmitis after an injection from Master Lot #11222013@66
C. Your firm's personnel stated that you received a complaint in mid-February 2014 regarding an eye infection .
No records were provided to demonstrate that a root cause was determined, an investigation was conducted, or ifit was determined whether any other batches were affected.
Observation 11
Routine calibration of equipment is not performed according to a written program des igned to assure proper performance.
Specifically, the Magnehelic guages , #1 and #2, used to monitor the pressure differentials for your ISO classified areas lacked current calibration records and were due for calibration 12/31/13. The following lots of Avastin finished product syringes were produced after 12/31/B:
01082014@5,01132014~12,01152014@75,01202014@9,01222014~3,01272014@69, 02042014@46, 02062014@62, 02182014@6, and 02192014@31.
This is a repeat observation and was listed as Observation 11 on the FDA 483 dated 07/26/13.
Linked 483s whose text is not shown
- Oct 4, 2016: FDA document 100171: the FEI number and firm name on its cover do not match this page by the rule.
- Jul 17, 2015: FDA document 86720: the PDF is a scanned image with no readable text.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH26249 | Pharmacy | WELLS PHARMACY NETWORK, LLC | OCALA | Clear |
| PH27462 | Pharmacy | WELLS PHARMACY NETWORK, LLC | OCALA | Clear |
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- May 12, 2025: “Administrative Complaint Filed”, license PH27462, case 202449572, WELLS PHARMACY NETWORK LLC, OCALA, FL. Board list
- Jul 9, 2020: “Obligation(s) Satisfied”, license PH26249, case 201940934, WELLS PHARMACY NETWORK LLC, OCALA, FL. Board list
- Dec 16, 2019: “Administrative Complaint Filed”, license PH26249, case 201940934, WELLS PHARMACY NETWORK LLC, OCALA, FL. Board list
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License PH25799, WELLS PHARMACY NETWORK LLC, WELLINGTON, status Closed: same name and state, different city.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NRP 1333 | Non Resident Pharmacy | Wells Pharmacy Network Llc | Ocala, FL | Active |
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6079 | OSP | Wells Pharmacy Network, LLC | Ocala, FL | Active |
- Apr 8, 2025: “CLS Letter of Admonition”, license OSP 6079, case 2024-9567, Wells Pharmacy Network, LLC, Ocala, FL. Board document
- Jun 13, 2023: “CLS Letter of Admonition”, license OSP 6079, case 2023-1278, Wells Pharmacy Network, LLC, Ocala, FL. Board document
- Oct 31, 2018: “CLS Letter of Admonition”, license OSP 6079, case 2018-4901, Wells Pharmacy Network, LLC, Ocala, FL. Board document
- May 18, 2017: “CLS Stipulation”, license OSP 6079, case 2015-2415, Wells Pharmacy Network, LLC, Ocala, FL. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054018020 | LICENSED PHARMACY | WELLS PHARMACY NETWORK LLC | OCALA, FL | INOPERATIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002385 | NONRESIDENT PHARMACY | WELLS PHARMACY NETWORK LLC | OCALA, FL | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0001159 | Non Resident Pharmacy | Wells Pharmacy Network, LLC | OCALA, FL | Active |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301009886 | Pharmacy | Wells Pharmacy Network LLC | Ocala, FL | Active |
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Florida Board of Pharmacy disciplinary records
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.